More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$522547498
EPS
-4.46
P/E ratio
--
Price to sales
0.22
Dividend yield
--
Beta
1.033114
Previous close
$4.83
Today's open
$4.75
Day's range
$4.59 - $4.82
52 week range
$2.10 - $6.26
show more
CEO
Seth Blackley
Employees
4200
Headquarters
Arlington, VA
Exchange
New York Stock Exchange
Shares outstanding
113105519
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
What Evolent Health (EVH) Said on Its Q3 Earnings Call
Evolent Health NYSE: EVH raised the lower end of its 2026 adjusted earnings outlook after third-quarter revenue and profitability improved from the preceding quarter, helped by growth in its Performance Suite business and favorable claims development.
MarketBeat • Nov 7, 2026

Evolent Health, Inc. (EVH) Q3 2026 Earnings Call Transcript
Evolent Health, Inc. ( EVH ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Seth Blackley - Co-Founder, CEO & Director Mario Ramos - Chief Financial Officer Conference Call Participants Zachary Haggerty - KeyBanc Capital Markets Inc., Research Division Richard Close - Canaccord Genuity Corp., Research Division Jailendra Singh - Truist Securities, Inc., Research Division Dustin Scaringe - William Blair & Company L.L.C., Research Division Kevin Meli - RBC Capital Markets, Research Division Sahil Veeramoney - Piper Sandler & Co., Research Division Matthew Shea - Needham & Company, LLC, Research Division David Larsen - BTIG, LLC, Research Division Presentation Operator Good morning, and welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2026.
Seeking Alpha • Nov 7, 2026

Evolent Announces Third Quarter 2026 Results
WASHINGTON, Nov. 5, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us.
PRNewsWire • Nov 5, 2026

Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Nov 5, 2026

Evolent Health (EVH) Matches Q3 Earnings Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, before market open, with a conference call to follow at 8:30 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
PRNewsWire • Oct 9, 2026

TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
TransPerfect expands its Evolent partnership to provide enterprise-wide telephonic interpretation and strengthen language access for health plan members.
GlobeNewsWire • Sep 21, 2026

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming
Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.
Seeking Alpha • Aug 13, 2026

Evolent Health Q2 Earnings Call Highlights
Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.
MarketBeat • Aug 8, 2026

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Evolent Health Inc Class A commission-free¹. Build wealth for the long term using automated trading and transfers.